博晖创新(300318.SZ)：控股孙公司联合获得药物临床试验批准通知书

Core Viewpoint - The company BoHui Innovation (300318.SZ) announced that its subsidiary BoHui Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of a lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine [1] Group 1 - The lyophilized Hib conjugate vaccine is developed in collaboration with Beijing Baihui Biotechnology Co., Ltd. [1] - The vaccine aims to stimulate immune response through a purified Hib capsular polysaccharide antigen combined with tetanus toxoid, targeting invasive infections caused by Hib, such as meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [1]